Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- AZ, SCC to Help Elimination of Drug Lag through Joint Research
September 1, 2008
- Prasugrel Inhibits Recurrence of CV Events More Effectively than Clopidogrel
September 1, 2008
- REGULATORY NEWS IN BRIEF
September 1, 2008
- MCHC Aims at Developing Comprehensive Healthcare Businesses: President Kobayashi
September 1, 2008
- Largest Number of Drugs Unavailable in Japan among 11 Countries: OPIR Survey
September 1, 2008
- Depression Linked to Changes in Cerebral Blood Flow
September 1, 2008
- Criteria for Use of Thalidomide Announced
September 1, 2008
- Wholesalers' SGA Expense Ratio Drops to below 7% for the First Time
August 25, 2008
- Eliminating Losses due to Invoice Prices Higher than Sales Prices Is Not Easy: Mr Matsutani
August 25, 2008
- SSP Aims at Growth Rate 2 Points Above Industry Average: President Hatori
August 25, 2008
- Price Settlement Rate Reaches 53% as of July 31: Mediceo Paltac
August 25, 2008
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
August 25, 2008
- Price Settlement Rates as of End of June Similar to Those Reported 2 Years Ago
August 25, 2008
- 13th ACCJ Media Lectures
August 25, 2008
- Bayer, FUJIFILM RI Pharma Start Receiving Orders on Zevalin
August 25, 2008
- Market Price Surveys to Focus on Generics
August 25, 2008
- Pfizer Starts Detailing Macugen for AMD
August 25, 2008
- R&D NEWS IN BRIEF
August 25, 2008
- Top Management Changes Made within 2 Months Announced by Ono
August 25, 2008
- Development of New Drugs for AMD Stimulated
August 25, 2008
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…